WhiteSwell is a patient-focused company dedicated to improving treatment of acute decompensated heart failure (ADHF), a primary cause of repeat hospitalization and emergency room visits.

Acute decompensated heart failure, characterized by a rapid onset of fluid volume overload, leads to over one million hospital admissions annually in the U.S. alone.

Early dapagliflozin initiation was safe across all diabetic and cardiorenal in-hospital outcomes, with no differences between treatment groups in the change in eGFR from baseline to end-of-study ...

A Phenomapping Tool and Clinical Score to Identify Low Diuretic Efficiency in Acute Decompensated Heart Failure. JACC: Heart Failure, 2023; DOI: 10.1016/j.jchf.2023.09.029 ...

In ADHF, sarcopenia and hypoalbuminemia have both been found to be independent prognostic factors for adverse outcomes such as mortality and hospital readmission. However, their impact when they ...

March 26, 2007 (New Orleans, LA) - Adding the oral vasopressin antagonist tolvaptan (Otsuka Inc) to standard IV therapy in patients hospitalized with acute decompensated heart failure (ADHF ...

Catheter Precision to Acquire Assets in Development for Late-Stage Treatment for Acute Decompensated Heart Failure Provided by GlobeNewswire Apr 23, 2025 5:00am ...

The preliminary results from the STIM-ADHF and STOP-ADHF studies suggest that CPNS therapy may address the large unmet need for alternative, and more effective, treatment options for patients ...

Catheter Precision to Acquire Assets in Development for Late-Stage Treatment for Acute Decompensated Heart Failure Published Apr 23, 2025 8:00am EDT ...

Catheter Precision to Acquire Assets in Development for Late-Stage Treatment for Acute Decompensated Heart Failure Apr. 23, 2025 8:00 AM ET Catheter Precision, Inc. (VTAK) ...